Publications

2021

Daman AW, Josefowicz SZ. Epigenetic and transcriptional control of interferon-β. J Exp Med. 2021;218(9).
Chen B-, Wang Y, Tubbs A, Zong D, Fowler FC, Zolnerowich N, et al. LIN37-DREAM prevents DNA end resection and homologous recombination at DNA double-strand breaks in quiescent cells. Elife. 2021;10.
Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al. Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year. bioRxiv. 2021.
Zhang Z, Bai H, Blumenfeld J, Ramnauth AB, Barash I, Prince M, et al. Detection of PKD1 and PKD2 Somatic Variants in Autosomal Dominant Polycystic Kidney Cyst Epithelial Cells by Whole-Genome Sequencing. J Am Soc Nephrol. 2021;32(12):3114-3129.
Adib E, Nassar AH, Akl EW, Alaiwi SA, Nuzzo PV, Mouhieddine TH, et al. CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. Clin Cancer Res. 2021;27(14):4025-4035.
Pappa T, Ahmadi S, Marqusee E, Johnson HL, Nehs MA, Cho NL, et al. Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in BRAFV600E -Driven Papillary Thyroid Cancer Patients. Clin Cancer Res. 2021;27(15):4256-4264.
Karkampouna S, La Manna F, Benjak A, Kiener M, De Menna M, Zoni E, et al. Patient-derived xenografts and organoids model therapy response in prostate cancer. Nat Commun. 2021;12(1):1117.
Morel KL, Sheahan AV, Burkhart DL, Baca SC, Boufaied N, Liu Y, et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021;2(4):444-456.
Cejas P, Xie Y, Font-Tello A, Lim K, Syamala S, Qiu X, et al. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun. 2021;12(1):5775.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700